The trial used a previously developed method to integrate ischemic and bleeding events as "ischemic stroke equivalents" to compare weighted benefit of two doses of dabigatran with each other and with warfarin.
The trial results have been presented at the American Heart Association Scientific Sessions, Los Angeles, US.
The data collected from 18,113 patients during the trial, has reiterated the benefits of dabigatran etexilate and has also provided physicians an approach to tailor treatment based upon individual patient characteristics and patient and physician preferences.